Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries, a generic pharmaceutical company, has received the FDA approval for the company's abbreviated new drug application to market its generic version of AstraZeneca's Pulmicort Respules, 0.25mg/2ml and 0.5mg/2ml indicated for twice daily treatment of asthma.
Subscribe to our email newsletter
Shipment of these products has commenced. Teva is currently involved in patent litigation concerning this product in the US District Court of New Jersey. A trial has been scheduled for January 12, 2009.